Hemodynamic effects of newer antiarrhythmic drugs

Jewitt, D. E.

doi:10.1016/0002-8703(80)90201-x

Cited by 39 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, because each point on the FBF curve is based on the angle of the plethysmographic curve over five cardiac cycles, this averaging effect may attenuate the beat-to-beat variations and limit their influence. Fourth, the types of antihypertensive (32) and antiarrhythmic drugs (33) and the dosage of statins (34) may have influenced the FMD values in patients with non-valvular AF. Fifth, the present study is a retrospective study analyzing the FMD, and we cannot completely exclude the possibility of bias despite carefully matching for age, gender and CHA 2 DS 2 -VASc scores among the three groups.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Impairment of the Vascular Endothelial Function and the CHA2DS2-VASc Score in Patients with Sinus Rhythm and Non-valvular Atrial Fibrillation

et al. 2018

View full text Add to dashboard Cite

Objective and methods There is little information concerning the influence of the heart rhythm on the vascular endothelial function in patients with non-valvular atrial fibrillation (AF) compared with studies concerning sinus rhythm (SR). The present study included paroxysmal (n=184) or chronic (n=53) AF patients without heart failure and control subjects with SR (n=79) matched for age, gender and the CHA2DS2-VASc score. Paroxysmal AF was defined as episodes that terminated spontaneously within 7 days, while chronic AF was defined as longstanding AF that was refractory to cardioversion for 12 months or longer. There were no significant differences in the numbers of patients receiving renin-angiotension-aldosterone system inhibitors or statins among the three groups. Results Among the 237 AF patients (155 men, mean age 64±9 years, mean CHA2DS2-VASc score 1.8±1.4), the flow-mediated dilatation (FMD) was 5.4%±2.6% in the paroxysmal AF group, 4.3%±2.1% in the chronic AF group and 6.5%±3.5% in the SR group. There were significant differences among the 3 groups (all, p<0.05). Nitroglycerin-induced dilatation (NMD) was noted in 14.6%±6.5% of the paroxysmal AF group, 16.5%±9.1% of the chronic AF group and 12.7%±5.9% of the SR group, with no significant differences among the 3 groups. There was a significant negative correlation between the CHA2DS2-VASc scores and the FMDs value in all 3 groups (paroxysmal AF group:r=-0.322, p<0.01; chronic AF group:r=-0.291, p<0.05; SR group:r=-0.326, p<0.01). Conclusion In comparison with SR, the frequency and duration of AF episodes appear to cause deterioration of the vascular endothelial function.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between Impairment of the Vascular Endothelial Function and the CHA2DS2-VASc Score in Patients with Sinus Rhythm and Non-valvular Atrial Fibrillation

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the present study, the patients were given either aprindine or cibenzoline for at least 2 weeks before cardioversion and throughout the study and these agents have endothelium-independent vasoacting properties in higher doses. 25,26 However, because they were not discontinued for the study, their influence on the improvement of endothelial function after cardioversion is eliminated. Third, this study is limited by the relatively small number of subjects studied, which limits the statistical power of the data, possibly masking changes in hemodynamics before and after cardioversion.…”

Section: Study Limitationsmentioning

confidence: 99%

Impaired Exercise-Induced Vasodilatation in Chronic Atrial Fibrillation. Role of Endothelium-Derived Nitric Oxide.

Takahashi

Ishibashi

Shimada

et al. 2002

Circ J

View full text Add to dashboard Cite

“…Long-term pain management with infusion therapy is impractical; therefore, attention has been directed to the use of oral analogues of lidocaine, including mexiletine and tocainide, after a positive response to intravenous lidocaine infusion testing [22,23]. Despite the demonstrated effectiveness of tocainide in trigeminal neuralgia and causalgia [24], the risks of agranulocytosis [25] and interstitial pneumonitis [26] have practically precluded its widespread clinical use.…”

Section: Local Anesthetic Agentsmentioning

confidence: 99%

Drug infusions for the diagnosis and treatment of chronic pain

O’Gorman

Raja

2002

Current Science Inc

View full text Add to dashboard Cite

Diagnostic infusion therapy has several advantages over other routes of drug administration in the management of chronic pain. Although systemic side effects may occur, the procedure is relatively noninvasive and is generally well tolerated by patients. Infusion techniques have a potential use in the blinded evaluation of a patient's response to a specific therapy, and thus may minimize placebo responses associated with the more invasive diagnostic nerve blocks. Infusion tests may be useful prognostic indicators of the potential efficacy of a class of oral drugs in a patient. This article reviews the scientific and clinical background behind the major classes of drugs used in diagnostic infusion testing, namely local anesthetics, opioids, and a-adrenergic blockers. Clinical application of these agents in the management of chronic pain also is outlined.

show abstract

Hemodynamic effects of newer antiarrhythmic drugs

Cited by 39 publications

References 20 publications

Relationship between Impairment of the Vascular Endothelial Function and the CHA<sub>2</sub>DS<sub>2</sub>-VASc Score in Patients with Sinus Rhythm and Non-valvular Atrial Fibrillation

Relationship between Impairment of the Vascular Endothelial Function and the CHA<sub>2</sub>DS<sub>2</sub>-VASc Score in Patients with Sinus Rhythm and Non-valvular Atrial Fibrillation

Impaired Exercise-Induced Vasodilatation in Chronic Atrial Fibrillation. Role of Endothelium-Derived Nitric Oxide.

Drug infusions for the diagnosis and treatment of chronic pain

Contact Info

Product

Resources

About